Chardan Capital Has Positive Outlook of LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at Chardan Capital upped their FY2025 EPS estimates for shares of Lexeo Therapeutics in a research note issued to investors on Tuesday, April 8th. Chardan Capital analyst G. Livshits now forecasts that the company will post earnings per share of ($3.06) for the year, up from their prior forecast of ($3.10). Chardan Capital currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.09.

A number of other brokerages have also recently issued reports on LXEO. Leerink Partners reduced their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research note on Monday, March 24th. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, April 8th. Finally, Royal Bank of Canada cut their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $22.20.

Remove Ads

Lexeo Therapeutics Stock Performance

Shares of NASDAQ:LXEO traded up $0.41 during mid-day trading on Friday, reaching $2.55. 684,066 shares of the company traded hands, compared to its average volume of 404,293. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $19.50. The firm has a market cap of $84.65 million, a PE ratio of -0.81 and a beta of 1.52. The company's 50 day moving average price is $3.25 and its 200-day moving average price is $5.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95.

Institutional Trading of Lexeo Therapeutics

A number of large investors have recently added to or reduced their stakes in LXEO. Allostery Investments LP bought a new stake in Lexeo Therapeutics in the fourth quarter worth $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at about $46,000. BNP Paribas Financial Markets lifted its holdings in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock valued at $50,000 after acquiring an additional 3,591 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Lexeo Therapeutics in the fourth quarter worth about $69,000. Finally, SG Americas Securities LLC purchased a new stake in Lexeo Therapeutics during the fourth quarter valued at approximately $72,000. Institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.